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To the Editor: The acquired form of long QT syndrome (LQTS)
is often induced by hypokalemia or drugs. Hypokalemia and
drugs cause QT prolongation via reduction in the rapidly
activating component of the delayed rectifier K currents (IKr).
Therefore, the KCNH2 (HERG) channel conducting IKr is
recognized as the most susceptible channel in acquired LQTS.
However, the autoimmune effect on the KCNH2 channel has
not been elucidated.
In the present report, we describe a female patient with an
acquired form of LQTS with no known cause of QT prolongation.
We used the patch clamp method (1) to determine whether her
serum and immunoglobulin (Ig)G reduced IKr, and we performed
Western blot analysis to determine whether her IgG included
anti-KCNH2 antibodies.
The patient was a 42-year-old female who had a normal
clinical history until recurrent episodes of syncope for 3 months.
An electrocardiogram (ECG) showed marked QT prolonga-
tion, T-wave alternans, and episodes of Torsades de pointes
(Fig. 1A). Treatment with atrial pacing (70/min) and intrave-
nous magnesium infusion were started, but the corrected QT
interval (QTc) was persistently prolonged (0.70 s0.5) (Fig. 1B).
The ECGs obtained at annual checkups for the previous 4 years
were normal or at most borderline (0.45 to 0.46 for women), but
with normal T-wave morphology and not suggestive of LQTS
(QTc 0.43 s0.5) (Fig. 1C), and there was no family history of
QT prolongation or cardiac sudden death. The patient was not
taking any drugs, and there was no evidence of structural heart
disease or cerebrovascular disease. Laboratory data, including
serum electrolytes and hormones, were normal except for
detection of increased IgG concentration (1,783 mg/dl) and
positive anti-Sjögren’s syndrome A (SSA)/Ro antibodies (141.3
index). The recurrence of syncope was diminished by oral
administration of atenolol (100 mg/day) and verapamil (120
mg/day). The patient was discharged after implantation of an
implantable cardioverter-defibrillator with pacing mode DDI
(lower: 70/min). Prolonged QT interval and increased IgG level
have remained, but ventricular tachycardia or fibrillation events
have not been detected.
We screened for known LQTS-associated genes by polymer-
ase chain reaction DNA conformation polymorphism analysis
and DNA sequencing. We suspected LQT2 because of low-
amplitude T waves in the ECG, but there was no mutation in
the KCNH2 gene. Furthermore, no mutation was detected in
KCNQ1, SCN5A, KCNE1, KCNE2, and KCNJ2 genes. There
was a polymorphism (D85N) in KCNE1, which is heterozy-
gously found in 2% of the Japanese population. Because ECGs
for the previous 4 years were normal, D85N-KCNE1 may have
not a causative but rather a modifying role in this LQTS
patient.
The KCNH2 current stably expressed in HEK 293 cells was
significantly reduced when cells had been cultured for 1 to 5
days in a medium to which 2% serum from the patient (Figs. 2A
and 2D) or IgG (75 g/ml) (Figs. 2B to 2D) had been added.
When cells expressing KCNH2 that had been cultured in the
patient’s serum were returned to the medium without serum
overnight, the amplitudes of both KCNH2 outward and tail
currents recovered to untreated levels. The patient’s serum had
no effect on the slowly activating components of the delayed
rectifier K currents (IKs) of HEK 293 cells expressing
KCNQ1/KCNE1 (data not shown). Next, we tested whether
the patient’s serum has an acute effect on KCNH2 currents (I).
Direct application of 2% serum from the patient to physiologic
solution for 5 min had no effect on either Istep or Itail. These
findings suggest that the patient’s IgG decreased KCNH2
expression. The mechanism is not clear, but endocytosis may be
facilitated.
Figure 1 Electrocardiogram Traces of a
Patient With Acquired QT Prolongation
(A) Marked QT prolongation and Torsades de pointes shown in 24-h electrocar-
diogram traces. (B) Prolonged QT interval was persistently observed after the
initial episodes (corrected QT interval [QTc] 0.70 s0.5). (C) Twelve-lead electro-
cardiogram 1 year before is normal (QTc 0.43 s0.5).
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In Western blotting of the lysate of HEK 293 cells express-
ing KCNH2, no band was detected in the presence of IgG from
a healthy control subject (Fig. 2E, lane 1). A single distinct
band of approximately 150 kDa was evident in the presence of
IgG from the patient (Fig. 2E, lane 2). This band was absorbed
by preincubation with the lysate of HEK 293 cells expressing
KCNH2 protein (Fig. 2E, lane 3). A band of the same size was
recognized in the presence of rabbit antiHERG polyclonal
antibodies (Alomone Labs, Jerusalem, Israel) (Fig. 2E, lane 4).
A 155-kDa (upper) band is a mature form of the KCNH2
channel and a 135-kDa (lower) band is a precursor form of the
KCNH2 channel (2). Figure 2B shows the upper band in the
presence of the patient’s IgG. Therefore, the patient’s IgG
contains autoantibodies against the mature form of KCNH2
protein.
Cross-reaction of anti-SSA/Ro antibodies with the L-type
calcium channel has been reported (3). Lazzerini et al. (4) have
also reported that patients with anti-SSA/Ro–positive connec-
tive tissue diseases show a high prevalence of QTc prolongation.
In the present study, the patient had positive anti-SSA/Ro
antibodies. Cross-reaction of anti-SSA/Ro antibodies with the
KCNH2 channel may be involved in the pathogenesis of
autoimmunity. Immunosuppressive therapy and reduction of
plasma IgG may be effective for QT-interval shortening in the
future. Further studies are needed to clarify this point.
In summary, our results show that abnormal IgG from a patient
with acquired LQTS reduces the KCNH2 current and that the
IgG includes anti-KCNH2 antibody. This is the first report of
anti-KCNH2 antibody-induced LQTS.
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Figure 2 KCNH2 (HERG) Channel Currents and Western Blot
Analysis of Autoantibodies Produced Against KCNH2
(A) Representative KCNH2 (HERG) channel currents recorded from HEK 293
cells cultured in control medium (left) and medium supplemented with 2%
serum from the patient (right). (B) Representative KCNH2 channel currents
recorded from HEK 293 cells cultured in control medium (left) and medium
supplemented with 75 g/ml immunoglobulin (Ig)G from the patient (right).
(C) Current (I)–voltage relationships of Istep (left) and Itail (right) recorded from
HEK 293 cells cultured in control medium (open circles; n  4) or a medium
supplemented with either 7.5 g/ml (solid circles; n  7) or 75 g/ml (solid
squares; n  7) IgG. The lines fitted to Itail data (right) represent Boltzmann
functions. (D) A comparison of the dose-dependent effects of serum (0.2% and
2%) and IgG (7.5 and 75 g/ml) added to the culture medium (control) of HEK
293 cells expressing KCNH2 on maximal Itail amplitude. (E) Western blot analy-
sis of autoantibodies produced against KCNH2. Lane 1: IgG from a healthy
control subject; lane 2: IgG from the patient; lane 3: pre-incubation of the HEK
293 lysate expressing KCNH2 protein with IgG from the patient; lane 4: anti-
KCNH2 polyclonal antibodies (positive control).
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